EA201490004A1 - Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей - Google Patents

Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей

Info

Publication number
EA201490004A1
EA201490004A1 EA201490004A EA201490004A EA201490004A1 EA 201490004 A1 EA201490004 A1 EA 201490004A1 EA 201490004 A EA201490004 A EA 201490004A EA 201490004 A EA201490004 A EA 201490004A EA 201490004 A1 EA201490004 A1 EA 201490004A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bifidobacterium lactis
treatment
application
respiratory diseases
subject
Prior art date
Application number
EA201490004A
Other languages
English (en)
Other versions
EA031426B1 (ru
Inventor
Дэвид Пайн
Николас Уэст
Аллан Криппс
Сампо Лахтинен
Original Assignee
ДюПон НЬЮТРИШН БАЙОСАЙЕНСИЗ АпС
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ДюПон НЬЮТРИШН БАЙОСАЙЕНСИЗ АпС filed Critical ДюПон НЬЮТРИШН БАЙОСАЙЕНСИЗ АпС
Publication of EA201490004A1 publication Critical patent/EA201490004A1/ru
Publication of EA031426B1 publication Critical patent/EA031426B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Настоящее изобретение относится к способу лечения или профилактики у субъекта заболевания дыхательных путей, включающему введение указанному субъекту композиции, содержащей Bifidobacterium lactis BL04, и/или продукт ферментации Bifidobacterium lactis BL04, и/или клеточный лизат Bifidobacterium lactis BL04.
EA201490004A 2011-06-10 2012-06-08 ПРИМЕНЕНИЕ Bifidobacterium lactis BL-04 ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ДЫХАТЕЛЬНЫХ ПУТЕЙ EA031426B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161495614P 2011-06-10 2011-06-10
GBGB1110095.5A GB201110095D0 (en) 2011-06-15 2011-06-15 Method of treatment
PCT/GB2012/051302 WO2012168732A1 (en) 2011-06-10 2012-06-08 Treatment of respiratory tract illness with bifidobacterium lactis bl-04

Publications (2)

Publication Number Publication Date
EA201490004A1 true EA201490004A1 (ru) 2014-09-30
EA031426B1 EA031426B1 (ru) 2018-12-28

Family

ID=44357821

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490004A EA031426B1 (ru) 2011-06-10 2012-06-08 ПРИМЕНЕНИЕ Bifidobacterium lactis BL-04 ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ДЫХАТЕЛЬНЫХ ПУТЕЙ

Country Status (9)

Country Link
US (4) US20140112897A1 (ru)
EP (1) EP2717889B1 (ru)
JP (1) JP6153517B2 (ru)
CN (1) CN104168905B (ru)
BR (1) BR112013031659B1 (ru)
EA (1) EA031426B1 (ru)
ES (1) ES2583695T3 (ru)
GB (1) GB201110095D0 (ru)
WO (1) WO2012168732A1 (ru)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
CN103705654B (zh) * 2014-01-14 2018-05-22 邓小莉 一种用于治疗鼻炎的填充枕芯中药药丸及其制备方法
CN103720762B (zh) * 2014-01-14 2018-05-22 邓小莉 治疗鼻炎蒸熏剂及其制备方法
AU2015370665B2 (en) 2014-12-23 2020-05-14 4D Pharma Research Limited Pirin polypeptide and immune modulation
CA2971108C (en) 2014-12-23 2019-09-17 4D Pharma Research Limited A bacteroides thetaiotaomicron strain and use thereof in reducing inflammation
JP6867953B2 (ja) * 2015-01-27 2021-05-12 デュポン ニュートリション バイオサイエンシーズ エーピーエス ビフィズス菌を含む免疫調節組成物
SG10201912326QA (en) 2015-06-15 2020-02-27 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PL3360559T3 (pl) 2015-06-15 2020-04-30 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
ES2753779T3 (es) 2015-06-15 2020-04-14 4D Pharma Res Ltd Blautia stercosis y wexlerae para la utilización en el tratamiento de enfermedades inflamatorias y autoinmunes
CN106256352A (zh) * 2015-08-19 2016-12-28 徐琳 用于减少与pm2.5暴露相关的肺部和/或全身性炎症的组合物及其用途
MA45287A (fr) 2015-11-20 2018-08-22 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
MX2018010680A (es) 2016-03-04 2019-06-13 4D Pharma Plc Composiciones que comprenden cepas bacterianas.
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
BR112019015792A8 (pt) * 2017-01-31 2023-01-03 Univ Kansas State Células microbianas, métodos de sua produção e usos destas
JP7212945B2 (ja) 2017-05-22 2023-01-26 フォーディー ファーマ リサーチ リミテッド 細菌株を含む組成物
TW201907931A (zh) 2017-05-24 2019-03-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
MD3638271T2 (ro) 2017-06-14 2021-03-31 4D Pharma Res Ltd Compoziții cuprizând tulpini bacteriene
ES2917415T3 (es) 2017-06-14 2022-07-08 4D Pharma Res Ltd Composiciones que comprenden una cepa bacteriana
CA3079562A1 (en) 2017-10-20 2019-04-25 Ms Biotech, Inc. Methods of producing ensiled plant materials using megasphaera elsdenii
WO2019151371A1 (ja) * 2018-01-31 2019-08-08 ニュートリー株式会社 肺炎球菌感染症の予防及び／又は治療剤
CN110055185B (zh) * 2018-12-25 2020-12-29 江南大学 一株具有抗流感能力的短双歧杆菌及其应用
CN110893193B (zh) * 2019-06-27 2023-03-24 内蒙古伊利实业集团股份有限公司 乳双歧杆菌bl-99的新应用
CN111560335B (zh) * 2020-05-26 2022-09-23 北京科拓恒通生物技术股份有限公司 一株用于缓解哮喘的乳双歧杆菌及其应用
US11318174B2 (en) * 2020-07-09 2022-05-03 Dupont Nutrition Biosciences Aps Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses
CN112402460A (zh) * 2020-12-14 2021-02-26 梁爱军 一种局部用益生菌液缩短感冒病程的方法
WO2023279093A1 (en) * 2021-07-01 2023-01-05 Duke University Compositions for and methods of promoting respiratory health
CN114470010B (zh) * 2022-02-07 2024-02-27 北京华元生物技术研究院 乳双歧杆菌bl-11的新用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20042189A1 (it) * 2004-11-16 2005-02-16 Anidral Srl Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale
WO2008053444A2 (en) * 2006-11-01 2008-05-08 The Procter & Gamble Company Treating a respiratory condition with bifidobacterium
NL1032840C2 (nl) * 2006-11-09 2008-05-13 Friesland Brands Bv Probiotische hydrolysaatvoeding voor kinderen.
JP5689601B2 (ja) * 2006-12-11 2015-03-25 デュポン ニュートリション バイオサイエンシーズ エーピーエス 組成物
DK2139502T3 (da) * 2007-03-26 2014-09-22 Dupont Nutrition Biosci Aps Lactobacillus og bifidobacterium mod birkeallergi
ITMI20072260A1 (it) * 2007-12-03 2009-06-04 Anidral Srl Una composizione a base di batteri probiotici in associazione con un prebiotico e suo uso nella prevenzione e/o nel trattamento di patologie e/o infezioni respiratorie e nel miglioramento della funzionalita intestinale.
CA2713525A1 (en) * 2008-02-06 2009-08-13 The Procter & Gamble Company Compositions methods and kits for enhancing immune response to a respiratory condition
CA2658440C (en) * 2008-04-04 2016-08-23 Kraft Foods Global Brands Llc Dairy composition with probiotics and anti-microbial system

Also Published As

Publication number Publication date
US20190269741A1 (en) 2019-09-05
ES2583695T3 (es) 2016-09-21
US20180036353A1 (en) 2018-02-08
EP2717889B1 (en) 2016-04-20
EP2717889A1 (en) 2014-04-16
GB201110095D0 (en) 2011-07-27
BR112013031659B1 (pt) 2021-08-31
CN104168905B (zh) 2018-12-04
US20140112897A1 (en) 2014-04-24
JP6153517B2 (ja) 2017-06-28
WO2012168732A1 (en) 2012-12-13
JP2014517003A (ja) 2014-07-17
EA031426B1 (ru) 2018-12-28
CN104168905A (zh) 2014-11-26
US20210379126A1 (en) 2021-12-09
BR112013031659A2 (pt) 2016-12-06

Similar Documents

Publication Publication Date Title
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
PH12019500439A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PH12014501702A1 (en) Imidazopyrrolidinone compounds
AU2011328009A8 (en) Compounds and methods for treating pain
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
BR112014009418A2 (pt) macrociclos peptidomiméticos
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
MX2022004300A (es) Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas.
UA112288C2 (uk) Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими
GEP201706786B (en) Methods and drug products for treating alzheimer's disease
IN2015DN00376A (ru)
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
GB201109238D0 (en) Antibodies
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
MX2014001393A (es) 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas.
WO2014028668A3 (en) Stem cell enhancing therapeutics
FI20115165A0 (fi) Terapeuttisia ja diagnostisia menetelmiä
EA201390417A1 (ru) Антидиабетические твердые фармацевтические композиции
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.
UA112981C2 (uk) Варіант людського gdnf
GB201115977D0 (en) Neurodevelopmental disorders
MX2013012551A (es) Uso de sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio en el tratamiento de enfermedades cardiovasculares.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM